Potential of GS and its derivatives in the prevention and treatment of cancer
Cancer | Model | Combination | Mechanism | References | |
---|---|---|---|---|---|
Brain tumor | In vitro | rBMECs | - | ↓P-gp, ↑P-gp ATPase | [134] |
In vitro | A172, U87MG, T98G | SANT-1 | ↑Caspase-3, -9, ↑cytochrome c, ↑Bax, ↑IκBα, ↓pIκKα/β, ↓NF-κB, ↓Ras, ↓p-STAT3, ↑ERK, ↓c-Myc | [140] | |
Breast cancer | In vitro | MCF-7 | IR | ↓NF-κB, ↓ERα, ↓IGF-1Rβ, ↑p21↑Radiosensitivity | [172] |
In vitro | MCF-7/DOX | DOX | ↑Apoptosis, ↓drug-transport activity, ↓MRP1 | [174] | |
In vitro | MDA-MB-231, MCF-7 | - | ↑Apoptosis, ↑Caspase-3, ↓β-Catenin, ↓TCF, ↓c-Myc, ↓Cyclin D1, ↓survivin | [128] | |
In vitro | MCF-7 | - | ↓MMP-9, ↓p65/p50, ↓IκBα, ↓IKKαβ, ↓IKK/IκB/NF-κB axis | [117] | |
In vitro | MCF-7 | - | ↓MMP-9, ↓AP-1, ↓MAPK, ↓ERK, ↓JNK | [117] | |
In vivo | BALB/c mice | DOX | ↓Tumor growth, ↓Bcl-2, ↓P-gp | [138] | |
In vitro | MDA-MB-231 | Bex & DOX | ↑Apoptosis, ↓BCRP, ↓MDR proteins | [141] | |
CRC | In vitro | HT-29 | - | ↓STAT3, ↓ARNT, ↓VEGF, ↓MMP-2, -9 | [110] |
In vitro | HT-29 | - | ↓Procaspase-9, -3, ↓Bcl-2, ↓cIAP-1↑Fas, ↑caspase-8, ↑p-JNK, ↑p-cJun, ↑tBid | [72] | |
In vivo | nu/nu mice | - | ↓Tumor growth | [72] | |
In vitro | HT-29 | IR | ↓IGF-1Rβ, ↓NF-κB, ↑p21, ↑γH2AX | [172] | |
In vitro | H508, SNU-C4, HT-29 | - | ↓FXR, ↑EGFR, ↑Src, ↑ERK-1/2 | [177] | |
In vitro | HCT-116 | - | ↑p-53, ↓NF-κB, ↓Bcl-2, ↓cIAP-1, ↓survivin | [126] | |
CCA | In vitro | Sk-ChA-1, Mz-ChA-1 | - | ↑Caspase-9, -3, -8, ↑PARP, ↓Bcl-2, ↓survivin | [111] |
In vitro | HuCC-T1, RBE | - | ↑Caspase-9, -3, -8, ↑DR5, ↑tBid, ↓Bid, ↑p-JNK1/2, ↑p-p38, ↑p-ERK1/2, ↑P-eIF2α, ↑BiP, ↑GRP78, ↑CHOP | [130] | |
Esophageal cancer | In vitro | BE-derived cells | - | ↑Apoptosis, ↑Caspase-3 | [105] |
In vitro | Bic-1 | - | ↓CDX2 | [113] | |
In vitro | TE-3 | - | ↓Cell proliferation | [179] | |
TE-12, SKGT-4, SKGT-5 | - | ↓FXR, ↓RAR-β2, ↓COX-2, ↓MMP-9, ↑Caspase-9, -3, -8 | |||
In vivo | nu/nu mice | - | ↓Tumor growth | [179] | |
In vitro | SKGT-4, SKGT-5, TE-3, TE-12 | Amiloride | ↓Cell viability, ↑apoptosis | [180] | |
In vivo | nu/nu nude mice | Amiloride | ↓Tumor formation, ↓growth | [180] | |
In vitro | OE33, OE19 | - | ↓IκBα, ↓COX-2, ↓CDX-2, ↓PGE2 | [115] | |
GBC | In vitro | TGBC1, TGBC2 | - | ↓NF-κB p65, ↓MMP-2, ↓VEGF-C | [139] |
In vitro | TGBC1, TGBC2 | Gemcitabine | ↓NF-κB p65 | [139] | |
Haematological malignancies | In vitro | KBM-5 | - | ↓NF-κB, ↑Caspase, ↑PARP cleavage ↑TNF-induced apoptosis | [65] |
In vitro | U937 | - | ↓ΔΨm, ↓p-ERK, ↑ROS, ↑HO-1, ↓GSH | [202] | |
In vitro | U937 | - | ↓Cyclin D1, ↓cdc2, ↓Bfl-1, ↓XIAP, ↓cFLIP, ↓survivin, ↓Bcl-xL, ↓Bcl-2, ↓COX-2, ↓c-Myc, ↓IL-6, ↓IL-1β, ↓TNF,↑p21, ↑p27, ↑caspase-8, -9, -3,↑PARP, ↑BiD, ↑Bax, ↑cytochrome c, ↑JNK, ↓PI3K/Akt | [112] | |
In vitro | U266 | - | ↓STAT3, ↓c-Src, ↓p-JAK2, ↑SHP-1, ↓Bcl-2, ↓Bcl-xL, ↓Mcl-1, ↓cyclin D1, ↑Caspase-3, ↑PARP | [109] | |
In vitro | MM.1S | - | ↓STAT3 | [109] | |
In vitro | K562/DOX | - | ↓P-gp, ↓MDR | [135] | |
HCC | In vitro | Hep3B | - | ↑CHOP, ↑DR5, ↑ROS, ↑BiP, ↑p-IRE1, ↑p-JNK, ↑p-PERK, ↑eIF-2α, ↑ATF4 | [142] |
In vitro | Hep3B | TRAIL | ↓mtTMPt, ↑ Caspase-9, -3, -8, ↑PARP, ↓Bcl-2 | [142] | |
In vitro | HepG2 | - | ↓Bcl-2, ↑Bax, ↓TGF-β1, ↓VEGF, ↑TNF-α | [125] | |
In vitro | HepG2R | - | ↓COX-2, ↓P-gp | [137] | |
In vitro | PLC/PRF/5R | DOX | ↓COX-2, ↓P-gp, ↓PGE2, ↓MDR | [137] | |
In vitro | HuH-7 | - | ↓EMT, ↓NR0B2, ↓CDH2 (N-cadherin) | [106] | |
HNC | In vitro | SCC4 | - | ↓STAT3 | [109] |
In vitro | PCI-37a, UM-22b, 1483 | - | ↓STAT-3, ↓HIF-1α | [108] | |
In vivo | Nude mice | - | ↑Apoptosis, ↓STAT-3 | [108] | |
In vitro | SCC4 | - | ↓Cyclin-D1, ↓XIAP, ↓Mcl-1, ↓c-Myc, ↓Survivin, ↑caspase-9, -3, -8, ↑Fas/CD95, ↑Bax/Bcl2, | [133] | |
In vitro | SCC4, HSC2 | - | ↓PI3K/Akt, ↓GSK3β, ↓PDK1, ↓p-Raf, ↓pS6, ↓p-Bax, ↓p-Bad | [66] | |
In vitro | SCC4, HSC2 | - | ↓p-IκBα, ↓NF-κB p65, ↓COX-2, ↓IL-6, ↓p-STAT-3, ↓VEGF | [123] | |
Lung cancer | In vitro | H1299 | - | ↓NF-κB, ↓IκBα, ↓IKK, ↓COX-2, ↓MMP-9, ↓VEGF, ↓Cyclin D1, ↓c-Myc, ↓cIAP1, ↓XIAP, ↓Bfl-1, ↓Bcl-2, ↓TRAF1, ↓cFLIP, ↓survivin | [65] |
Pancreatic cancer | In vitro | MIAPaCa-2, Panc-1 | Gemcitabine | ↓Bcl-2, ↓p-Akt, ↓NF-κB, ↑Bax, ↑p-JNK | [211] |
In vivo | BALB/c Nude Mice | Gemcitabine | ↓NF-κB, ↓Akt, ↓Bcl-2, ↑JNK | [211] | |
In vitro | CD18/HPAF, Capan1 | - | ↓XIAP, ↓Bcl2, ↓Cyclin D1, ↑BAD, ↑Bax, ↓MUC4, ↑Caspase-3, ↓JAK/STAT, ↓Src/FAK | [67] | |
In vitro | MIAPaCa2, PANC-1 | - | ↓FXR | [209] | |
In vitro | PC-sw | IR | ↓IGF-1Rβ, ↓NF-κB | [172] | |
In vitro | PANC-1 | - | ↓Akt | [210] | |
PC | In vitro | PC-3 | - | ↓Bcl-2, ↓Bcl-xL, ↑Bax, ↑Bak, ↑caspase-9, -3, -8 | [94] |
In vitro | PC-3, LNCaP | - | ↑JNK1/2, ↑p38 MAPK, ↑ERK1/2 | [131] | |
In vitro | DU145, HUVEC | - | ↓VEGF, ↓G-CSF, ↓IL-17, ↓MMP-2, ↓p-Akt, ↓VEGF-R2, | [218] | |
In vivo | DU145 cells implanted nude mice | - | ↓VEGF-R2, ↓factor VIII, ↓CD31 | [218] | |
Skin cancer | In vivo | SENCAR mice | - | ↓Skin edema, ↓hyperplasia, ↓ODC activity, ↓COX-2, ↓iNOS, ↓MAPKs, ↓NF-κB, ↓IKKα, ↓IκBα | [124] |
In vitro | B16/F10 mouse melanoma | - | ↓Melanogenesis, ↓tyrosinase, ↓TRP-1 ↓TRP-2, ↓MITF | [219] |
A Cis-GS; B Trans-GS; C GS derivatives, GSD1 & GSD7; AP-1: activator protein 1; Bex: Bexarotene; BiP: binding immunoglobulin protein; cIAP-1: cellular inhibitor of apoptosis protein 1; HIF-1α: hypoxia-inducible factor 1alpha; IL-6: interleukin-6; iNOS: inducible nitric oxide synthase; MM: multiple myeloma; MMP-2: matrix metalloproteinase-2; mtTMPt: mitochondrial transmembrane potential; ODC: ornithine decarboxylase; STAT-3: signal transducer and activator of transcription 3; tBid: truncated Bid
The author Kishore Banik acknowledges UGC, New Delhi, India, for providing him the fellowship.
ABK contributed to the study design, conceptualisation, supervision and review editing. SG, CH, and KB performed bibliographic search. SG and CH contributed to original manuscript. DP contributed to table preparation and proofreading. KB and DP performed artwork. CH, KB and DP contributed to review editing. SG, CH and KB contributed to proofreading.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
This project was supported by NCD/NER/4/2018-19 awarded to ABK by Indian Council of Medical Research (ICMR), Government of India. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2020.